Boehringer Ingelheim, WellPoint deal

Boehringer and WellPoint’s HealthCore Inc. unit have identified non-valvular atrial fibrillation (NVAF) as the

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE